Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 821 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR 120 years of Cancer Research UK: how science transformed survival rates December 19, 2022 De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... March 20, 2024 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... September 23, 2024 Load more HOT NEWS Coronavirus and COVID-19: What People With Cancer Need to Know FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or... Cancer and Climate Change: The Health Threats of Unnatural Disasters Does Sugar Cause Cancer?
